Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502534 | 0.88 | ALPL (0.56) | ALPLAAK1DGAT1CA1CA2 | |
| SCHEMBL9953472 | 0.85 | ALPL (0.62) | ALPLAAK1DGAT1CA1CA2 | |
| SCHEMBL9954248 | 0.85 | ALPL (0.54) | ALPLAAK1DGAT1CA1CA2 | |
| SCHEMBL790689 | 0.84 | ALPL (0.51) | ALPLAAK1LMNASMN1; SMN2 | |
| SCHEMBL798817 | 0.83 | ALPL (0.60) | ALPLAAK1DGAT1CA1CA2 | |
| SCHEMBL9954366 | 0.83 | ALPL (0.50) | ALPLLMNASMN1; SMN2 | |
| SCHEMBL14317978 | 0.83 | ALPL (0.50) | ALPLLMNASMN1; SMN2 | |
| SCHEMBL9953660 | 0.82 | ALPL (0.59) | ALPLAAK1DGAT1CA1CA2 | |
| SCHEMBL9954614 | 0.82 | ALPL (0.52) | ALPLAAK1DGAT1CA1CA2 | |
| SCHEMBL14317989 | 0.82 | ALPL (0.59) | ALPLAAK1DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179578-A1 | OX1 ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-06-17 | — | — | US | disclosed |
| US-20210179578-A1 | OX1 ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-06-17 | — | — | US | disclosed |
| EP-3710435-A1 | OX1 ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2020-09-23 | — | — | EP | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179578-A1 | OX1 ANTAGONISTS | HCRTR1, HCRTR2, OXTR | ALPL 4819/4885AAK1 931/4885DGAT1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.